Report #2844668

Received Jun 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 52 yrs
State: MD
Recovered: Unknown
Vaccinated: Jun 2, 2025
Onset: Jun 2, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	75D3A	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Early 2nd dose.; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 52-year-old female patient who received Herpes zoster (Shingrix) (batch number 75D3A, expiry date 31-MAR-2027) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 02-JUN-2025, the patient received the 2nd dose of Shingrix. On 02-JUN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Early 2nd dose.). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK receipt date: 05-JUN-2025 On 05/Jun/2025, a nurse called to inform about the early administration of the 2nd dose of Shingrix to a patient, according to reporter, first dose was given back in 11/Apr/2025, and the 2nd dose was administered on 2/Jun/2025 which led to which led to shortening of vaccinations schedule.

Other medications

SHINGRIX